Real-World Clinical Outcomes in Relapsed/Refractory Multiple Myeloma Treated With Pomalidomide Regimens

Inclusion criteria

• Have a diagnosis of multiple myeloma (ICD-9: 203.00; ICD-10: C90.0x, C90)
• Are ≥18 years of age at the index date
• Have received a lenalidomide-containing regimen and received a proteasome inhibitor; exposures do not need to occur within the same line of therapy
• Have received ≥1 subsequent lines of therapy after lenalidomide and proteasome inhibitor exposure
• Have received one of the following treatment regimens as the subsequent line (index line) after lenalidomide and proteasome inhibitor exposure:

• Pomalidomide-containing regimens:
• Daratumumab, pomalidomide, and dexamethasone (DPd)
• Carfilzomib, pomalidomide, and dexamethasone (KPd)

• Non-pomalidomide-containing regimens:
• Daratumumab, lenalidomide, and dexamethasone (DRd; lenalidomide-refractory participants only)
• Daratumumab, bortezomib, and dexamethasone (DVd)
• Daratumumab, carfilzomib, and dexamethasone (DKd)

Exclusion criteria

• Have <6 months of follow-up from the index date; participants who died will be included even with <6 months follow-up, but participants who died within 1 month after the index date will be excluded
• Have <6 months pre-index enrollment
• Have other primary cancer diagnoses within 1 year pre-index

• Excluded ICD-10 diagnosis codes: C00.xx-C76.xx, C7A, C80.xx-C88.xx, C91.xx-C96.xx, D00.xx-D09.xx, D37.xx-D47.1x, D47.3x-D49.xx
• Excluded ICD-9 diagnosis codes: 149.x through 239.x
• ICD codes 209.4, 209.5, 209.6, 209.7, D47.Z1, D47.Z2, and D3A will not be excluded
• Received chimeric antigen receptor T-cell therapy or bispecific antibody therapy before index date or as the index line
• Have ever enrolled in a clinical trial